CN104825478A - Drug composition for treating milk cow endometritis, and perfusion liquid preparation method thereof - Google Patents
Drug composition for treating milk cow endometritis, and perfusion liquid preparation method thereof Download PDFInfo
- Publication number
- CN104825478A CN104825478A CN201510174293.XA CN201510174293A CN104825478A CN 104825478 A CN104825478 A CN 104825478A CN 201510174293 A CN201510174293 A CN 201510174293A CN 104825478 A CN104825478 A CN 104825478A
- Authority
- CN
- China
- Prior art keywords
- parts
- pharmaceutical composition
- cow endometritis
- endometritis
- cow
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Abstract
The present invention discloses a drug composition for treating milk cow endometritis, and a preparation method thereof, wherein the drug composition is prepared from the following components by weight: 4-8 parts of tanshinone IIA, 3-5 parts of phillyrin, and 1-2 parts of stachydrine hydrochloride. According to the present invention, the three drugs are prepared into the uterine perfusion agent, such that effects of bacterial inhibiting, anti-inflammation, uterine contraction promoting, and uterus function recovery promoting are provided, the milk cow endometritis treating effect is significant, the cure rate achieves more than or equal to 87%, and the effective rate achieves more than or equal to 90%; and the drug composition has characteristics of safety on animals, no mucous membrane irritation, avoidance of antibiotic residue, drug resistance and other problems, and environmental protection.
Description
Technical field
The present invention relates to veterinary drug preparation field, be specifically related to a kind ofly be used for the treatment of the pharmaceutical composition of cow endometritis and the preparation method of infusion liquid thereof.
Background technology
Cow endometritis is the inflammation betiding cow uteri inner membrance, and being common a kind of genital organ disease in milch cow puerperal, is also the one of the main reasons causing milch cow infertile.Endometritis often causes Uterine And Cervical Involution In The Cow to postpone, follicular development and dysfunction, and reproductive capacity declines, calving interval prolongation, Repeat breeding, milk yield declines, cause medical expense and mortality to increase, economic benefit reduces, and causes serious economic loss to milk cow production.20% ~ 50% is about at the sickness rate of China's cow endometritis.The economic loss caused at German cow endometritis and vaginitis accounts for 50% of milch cow reproductive diseases in puerperal, and the U.S. is annual because barrenness of milk cow loss reaches 2.5 hundred million dollars, and the infertility of 60%-95% is caused by endometritis.According to estimates, every infect endometritis milch cow lactation period average cost be 106 dollars, the economic loss that milch cow is caused after suffering from hysteropathy puerperal reaches 285 dollars/head; Show according to research; milch cow suffers from after endometritis, and calving interval can extend 2 weeks even 2 months, and the economic loss of every cow head every day is about 2.5-5.4 dollar according to estimates; if within 1 month, calculated according to average calving interval prolongation, the economic loss of every cow head is 75-162 dollar.Visible, the economic loss that cow endometritis causes is very huge.At present, the Therapeutic Method of endometritis has local treatment, constitutional treatment and biological therapy, medicine mainly contains antibiotic, hormone, antiseptic and disinfectant drug and Chinese herbal medicine, and these medicines have certain curative effect to cow endometritis, but also has many shortcomings.Antibiotic and hormone play huge effect in control cow endometritis, but along with the prolongation of its Applicative time, toxic and side effects and drug resistance are not only there is, cause milch cow reproductive endocrine disorders, and easily at Residues in Milk, curative effect reduces, and even causes to abandon milk or reduce milk valency and sells, also can the health of harm humans time residual serious.Chinese medicine is efficient with it, low toxicity, low-residual and not easily produce the favor that the advantages such as drug resistance are more and more subject to Chinese scholars.Utilize Chinese medicine not only can prevent and treat cow endometritis, and its regulating action to body can be played, avoid the problem such as antibiotic remains and drug resistance, and environmental protection.
Summary of the invention
Object of the present invention is exactly for above-mentioned defect of the prior art, provide one and not only can prevent and treat cow endometritis, also can play its regulating action to body, avoid the problem such as antibiotic remains and drug resistance, and the pharmaceutical composition being used for the treatment of cow endometritis of environmental protection.
To achieve these goals, technical scheme provided by the invention is: a kind of pharmaceutical composition being used for the treatment of cow endometritis, is to be prepared by the following component according to parts by weight: Tanshinone II
a4 ~ 8 parts, phillyrin 3 ~ 5 parts, stachydrine hydrochloride 1 ~ 2 part.
Further, above-mentioned a kind of pharmaceutical composition being used for the treatment of cow endometritis is prepared by the following component according to parts by weight: Tanshinone II
a6 parts, phillyrin 3 parts, stachydrine hydrochloride 1 part.
Second object of the present invention there is provided a kind of preparation method being used for the treatment of the pharmaceutical composition infusion liquid of cow endometritis, comprises the following steps:
1) according to above-mentioned proportioning, Tanshinone II is taken
a40 ~ 80g, phillyrin 30 ~ 50g, stachydrine hydrochloride 10 ~ 20g, be ground into fine powder, and mixing, obtains hybrid medicine powder;
2) in the hybrid medicine powder obtained in step 1), add Polyethylene Glycol-200 8000mL, 60 DEG C of water-bath 2h, stir evenly, are cooled to room temperature, with the centrifugal 20min of 4000r/min, add Polyethylene Glycol-200 again after being merged by supernatant and be settled to 10000mL, be sub-packed in Brown Glass Brown glass bottles and jars only, 100mL/ bottle, 100 DEG C of sterilizing 30min, obtain pharmaceutical composition infusion liquid.
Further, above-mentioned a kind of preparation method being used for the treatment of the pharmaceutical composition infusion liquid of cow endometritis, comprises the following steps:
1) according to above-mentioned proportioning, Tanshinone II is taken
a60g, phillyrin 30g, stachydrine hydrochloride 10g, be ground into fine powder, and mixing, obtains hybrid medicine powder;
2) in the hybrid medicine powder obtained in step 1), add Polyethylene Glycol-200 8000mL, 60 DEG C of water-bath 2h, stir evenly, are cooled to room temperature, with the centrifugal 20min of 4000r/min, add Polyethylene Glycol-200 again after being merged by supernatant and be settled to 10000mL, be sub-packed in Brown Glass Brown glass bottles and jars only, 100mL/ bottle, 100 DEG C of sterilizing 30min, obtain pharmaceutical composition infusion liquid.
safety detects:
In order to measure the acute toxicity of Mouse oral trial drug, for data for clinical drug use provides foundation.Carry out trial test by the design of improvement karber's method, measure median lethal dose(LD 50) (LD
50), result mice all survives, and fails to find out minimal lethal dose, cannot measure LD
50therefore adopt maximum dosage-feeding method, 40 mices are divided into 2 groups at random, often organize 20, be respectively test group and matched group, test group is by every 1kg body weight 80ml pharmaceutical composition gavage, matched group presses 1kg body weight 80mL normal saline gavage, divides and gavages for 2 times, Continuous Observation 7d after administration, measure its maximum dosage-feeding on the 1st, determine the acute toxicity of trial drug.Result heavy dose of administration same day, test group mice spirit is depressed, and search for food, to drink water and autonomic activities reduces, the sleeping ground of some mice does not rise, and instability of gait during motion, administration recovers normal next day gradually.Continuous Observation 7d, all mices are glossy by hair, search for food, activity is all normal, without dead mouse.During off-test, test group and control group mice dissect after subcutaneous, the heart of perusal, liver, spleen, lung, the organ such as kidney and gastrointestinal tract is without obviously observing ANOMALOUS VARIATIONS.What show that trial drug can not cause parenchymal viscera observes pathology damage.Maximum dosage-feeding on the 1st of Mouse oral trial drug is 80ml/kg, is equivalent to 400 times of clinical milch cow (500kg) consumption per day, shows that trial drug is safer.
In order to investigate medicine to the zest of mucosa and local toxicity, rabbit the irritating experiment with eyes and Vaginal irritation effects test are carried out.Eye irritation, test and Selection 5 healthy rabbits, every day instills normal saline in experimental rabbits conjunctiva of left eye capsule, instillation medicinal liquid in conjunctiva of right eye capsule, each 0.1mL, rabbit eyes closed 8-10s is made with hands, continuous eye drip 7d, before each eye drip and the first local response situation of 6h observed and recorded eyes after eye drip, whether main detection rabbit cornea of both eyes is muddy, iris is with or without hyperemia, hemorrhage and swelling, pupil has reactionless to light, conjunctiva is with or without hyperemia, edema and flow point secretion etc., continue after drug withdrawal to observe 7d, by Eye irritation reaction standards of grading corneal, iris and conjunctiva are marked respectively, calculating mean value, the right and left eyes scoring of same rabbit is compared, make a determination by eye irritation evaluation criterion.Result shows, after trial drug eye drip, eye observation index and matched group no significant difference, show that this medicine is to rabbit eye irritation.
The irritation test of vaginal mucosa.Get rabbit 10, female, be divided into test group and matched group at random, often organize 5,1mL medicinal liquid injects in rabbit vagina by test group flexible pipe gently, keeps rabbit to lie on the back 5min, medicinal liquid is fully contacted with vaginal mucosa; Matched group pours into normal saline with method.Successive administration 7d, puts to death after last administration 24h, takes out vagina tissue, observes mucosa with or without the phenomenon such as congested, red and swollen, and vagina tissue is fixing in 10% formalin, paraffin section, and HE dyeing, carries out histopathologic examination.Result is compared with matched group, and test group vaginal mucosa is smooth, does not all occur the abnormal phenomena such as hyperemia, redness, and vagina tissue carries out paraffin section inspection, and mucous membrane tissue is all complete, change without exception.Show that trial drug is to mucosa nonirritant, mucosal drug delivery safety.
Beneficial effect of the present invention is:
In a kind of pharmaceutical composition being used for the treatment of cow endometritis provided by the invention and preparation method thereof, Tanshinone II
athere is inhibitory action to antibacterials such as staphylococcus, escherichia coli, Bacillus proteuss, also there is reparation and the regeneration of antiinflammatory and promotion tissue; Stachydrine hydrochloride has the effect of antibacterial and excited uterine smooth muscle; Phillyrin has inhibitory action to escherichia coli, staphylococcus, streptococcus, also has antiinflammatory action; These 3 kinds of medicines made uterine perfusion agent, has antibacterial anti-inflammatory, promote the effect that uterine contraction and uterus function recover, treatment cow endometritis is evident in efficacy, and cure rate reaches more than 87%, and effective percentage reaches more than 90%.This pharmaceutical composition, to animal safety, to mucosa nonirritant, can avoid the problem such as antibiotic remains and drug resistance, and environmental protection.
Detailed description of the invention
embodiment 1:
Be used for the treatment of a preparation method for the pharmaceutical composition infusion liquid of cow endometritis, comprise the following steps:
1) Tanshinone II is taken
a40g, phillyrin 40g, stachydrine hydrochloride 20g, be ground into fine powder, and mixing, obtains hybrid medicine powder;
2) in the hybrid medicine powder obtained in step 1), add Polyethylene Glycol-200 8000mL, 60 DEG C of water-bath 2h, stir evenly, are cooled to room temperature, with the centrifugal 20min of 4000r/min, add Polyethylene Glycol-200 again after being merged by supernatant and be settled to 10000mL, be sub-packed in Brown Glass Brown glass bottles and jars only, 100mL/ bottle, 100 DEG C of sterilizing 30min, obtain pharmaceutical composition.
embodiment 2:
Be used for the treatment of a preparation method for the pharmaceutical composition infusion liquid of cow endometritis, comprise the following steps:
1) Tanshinone II is taken
a80g, phillyrin 15g, stachydrine hydrochloride 5g, be ground into fine powder, and mixing, obtains hybrid medicine powder;
2) in the hybrid medicine powder obtained in step 1), add Polyethylene Glycol-200 8000mL, 60 DEG C of water-bath 2h, stir evenly, are cooled to room temperature, with the centrifugal 20min of 4000r/min, add Polyethylene Glycol-200 again after being merged by supernatant and be settled to 10000mL, be sub-packed in Brown Glass Brown glass bottles and jars only, 100mL/ bottle, 100 DEG C of sterilizing 30min, obtain pharmaceutical composition.
embodiment 3:
Be used for the treatment of a preparation method for the pharmaceutical composition infusion liquid of cow endometritis, comprise the following steps:
1) Tanshinone II is taken
a60g, phillyrin 30g, stachydrine hydrochloride 10g, be ground into fine powder, and mixing, obtains hybrid medicine powder;
2) in the hybrid medicine powder obtained in step 1), add Polyethylene Glycol-200 8000mL, 60 DEG C of water-bath 2h, stir evenly, are cooled to room temperature, with the centrifugal 20min of 4000r/min, add Polyethylene Glycol-200 again after being merged by supernatant and be settled to 10000mL, be sub-packed in Brown Glass Brown glass bottles and jars only, 100mL/ bottle, 100 DEG C of sterilizing 30min, obtain pharmaceutical composition.
embodiment 4:
Embodiment 3 is adopted to carry out practical application:
In July, 2012 to 2013 year December in cattle farm, area just outside a city gate, Lanzhou, Gansu holstein cow breeds the clinical trial that cow endometritis is carried out treating in 4 cattle farms such as demonstration centre cattle farm, the little western cattle cultivation company limited of Qin Wangchuan cattle farm, Gansu, Wuzhong City.Suffer from endometritis milch cow from vaginal orifice, discharge viscosity or sticky purulence rheuminess thing, hogback, exert duty and do posture of urinating repeatly, root of the tail and perineal position contaminated, when lying prone sleeping, output, increases.Discharge rheuminess thing though sometimes do not see, when oestrusing, in mucus, be mixed with pus, pus block or pus wadding.Sometimes ill milch cow non-estrus or the estrus cycle irregular.The ill Contents in Cows temperature rise of severe patient, spirit is depressed, and inappetence, ruminates and weaken, and milk yield reduces.Examination per rectum uterine contraction habituation, cornua uteri, body of uterus increase in various degree, and Uterus wall became uneven and quality soft or hard degree varies cause.Make a definite diagnosis 368 examples by clinical examination and examination per rectum, be divided into test group (264 example) and matched group (104 example) at random, test group every cattle uterus perfusion 100ml, matched group every cattle uterus perfusion 50ml oxytetracycline, the next day once, be for 4 times a course for the treatment of, treat 1 course for the treatment of.Result test group cures 230 examples, cure rate is 87.12%, invalid 24 examples, total effective rate is 90.91%, and matched group cures 83 examples, and cure rate is 79.81%, invalid 12 examples, total effective rate is 88.46%, and the cure rate of visible test group and total effective rate are all higher than matched group, and this illustrates that trial drug is evident in efficacy to cow endometritis.
Last it is noted that the foregoing is only the preferred embodiments of the present invention, be not limited to the present invention, although with reference to previous embodiment to invention has been detailed description, for a person skilled in the art, it still can be modified to the technical scheme described in foregoing embodiments, or carries out equivalent replacement to wherein portion of techniques feature.Within the spirit and principles in the present invention all, any amendment done, equivalent replacement, improvement etc., all should be included within protection scope of the present invention.
Claims (4)
1. being used for the treatment of a pharmaceutical composition for cow endometritis, it is characterized in that, is prepared by the following component according to parts by weight: Tanshinone II
a4 ~ 8 parts, phillyrin 3 ~ 5 parts, stachydrine hydrochloride 1 ~ 2 part.
2. a kind of pharmaceutical composition being used for the treatment of cow endometritis according to claim 1, is characterized in that, is to be prepared by the following component according to parts by weight: Tanshinone II
a6 parts, phillyrin 3 parts, stachydrine hydrochloride 1 part.
3. be used for the treatment of a preparation method for the pharmaceutical composition infusion liquid of cow endometritis, it is characterized in that, comprise the following steps:
1) according to proportioning according to claim 1, Tanshinone II is taken
a40 ~ 80g, phillyrin 30 ~ 50g, stachydrine hydrochloride 10 ~ 20g, be ground into fine powder, and mixing, obtains hybrid medicine powder;
2) in the hybrid medicine powder obtained in step 1), add Polyethylene Glycol-200 8000mL, 60 DEG C of water-bath 2h, stir evenly, are cooled to room temperature, with the centrifugal 20min of 4000r/min, add Polyethylene Glycol-200 again after being merged by supernatant and be settled to 10000mL, be sub-packed in Brown Glass Brown glass bottles and jars only, 100mL/ bottle, 100 DEG C of sterilizing 30min, obtain pharmaceutical composition infusion liquid.
4. be used for the treatment of a preparation method for the pharmaceutical composition infusion liquid of cow endometritis, it is characterized in that, comprise the following steps:
1) according to proportioning according to claim 2, Tanshinone II is taken
a60g, phillyrin 30g, stachydrine hydrochloride 10g, be ground into fine powder, and mixing, obtains hybrid medicine powder;
2) in the hybrid medicine powder obtained in step 1), add Polyethylene Glycol-200 8000mL, 60 DEG C of water-bath 2h, stir evenly, are cooled to room temperature, with the centrifugal 20min of 4000r/min, add Polyethylene Glycol-200 again after being merged by supernatant and be settled to 10000mL, be sub-packed in Brown Glass Brown glass bottles and jars only, 100mL/ bottle, 100 DEG C of sterilizing 30min, obtain pharmaceutical composition infusion liquid.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510174293.XA CN104825478B (en) | 2015-04-14 | 2015-04-14 | A kind of preparation method for being used to treat the pharmaceutical composition and its perfusion liquid of cow endometritis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510174293.XA CN104825478B (en) | 2015-04-14 | 2015-04-14 | A kind of preparation method for being used to treat the pharmaceutical composition and its perfusion liquid of cow endometritis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104825478A true CN104825478A (en) | 2015-08-12 |
| CN104825478B CN104825478B (en) | 2017-08-29 |
Family
ID=53803935
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510174293.XA Expired - Fee Related CN104825478B (en) | 2015-04-14 | 2015-04-14 | A kind of preparation method for being used to treat the pharmaceutical composition and its perfusion liquid of cow endometritis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104825478B (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1650950A (en) * | 2004-12-16 | 2005-08-10 | 中国农业科学院兰州畜牧与兽药研究所 | Traditional Chinese medicine for treating cow endo metritis |
| CN102552366A (en) * | 2012-02-14 | 2012-07-11 | 江西正邦动物保健品有限公司 | Chinese medicinal extract composition as female livestock uterus cleaning liquid |
-
2015
- 2015-04-14 CN CN201510174293.XA patent/CN104825478B/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1650950A (en) * | 2004-12-16 | 2005-08-10 | 中国农业科学院兰州畜牧与兽药研究所 | Traditional Chinese medicine for treating cow endo metritis |
| CN102552366A (en) * | 2012-02-14 | 2012-07-11 | 江西正邦动物保健品有限公司 | Chinese medicinal extract composition as female livestock uterus cleaning liquid |
Non-Patent Citations (5)
| Title |
|---|
| 严作廷 等: "中草药防治奶牛子宫内膜炎的现状及其药理作用机制", 《中国草食动物》 * |
| 崔洋 等: "河北道地药材连翘的高效液相色谱指纹图谱研究", 《中草药》 * |
| 秦美蓉 等: "盐酸益母草碱和盐酸水苏碱对大鼠离体子宫收缩的影响", 《今日药学》 * |
| 董书伟 等: "中药治疗牛子宫内膜炎的系统评价和Meta分析", 《畜牧兽医学报》 * |
| 郭文柱 等: "HPLC法测定中药"清宫液2号"隐丹参酮和丹参酮ⅡA的含量", 《中兽医医药杂志》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104825478B (en) | 2017-08-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106466454A (en) | A kind of prevention and the gel for the treatment of gynecological inflammation | |
| Cui et al. | Efficacy of herbal tincture as treatment option for retained placenta in dairy cows | |
| CN102000145B (en) | Traditional Chinese medicine and western medicine compound infusion liquid for preventing and treating endometritis of dam and preparing method thereof | |
| CN100586441C (en) | Compound sulfamonomethoxine sodium injection and preparation method thereof | |
| CN101897758A (en) | Traditional Chinese medicinal composition for curing animal womb inflammation and other postpartum diseases | |
| CN104721418A (en) | Pharmaceutical composition for treating gynecological inflammation and preparation method and use thereof | |
| CN102872300B (en) | Traditional Chinese medicine for treating non-gonococcal urethritis | |
| CN104825478B (en) | A kind of preparation method for being used to treat the pharmaceutical composition and its perfusion liquid of cow endometritis | |
| CN110507736B (en) | A Chinese medicinal perfusate for treating endometritis of female animal, and its preparation method | |
| Cui et al. | Prophylactic strategy with herbal remedy to reduce puerperal metritis risk in dairy cows: A randomized clinical trial | |
| CN104147530A (en) | Medicine for treating ectopic pregnancy and application thereof | |
| CN104306909B (en) | Prevent and treat Chinese medicine composition of cattle uterus subinvolution and preparation method thereof | |
| CN102357168B (en) | Chinese medicinal composition for treating gynecological diseases and preparation method thereof | |
| CN106138369A (en) | A kind of pharmaceutical composition preventing and treating animal endometritis and preparation method thereof | |
| CN1268355C (en) | Traditional Chinese medicine for treating cow endo metritis | |
| CN104208194B (en) | Traditional Chinese medicine composition for treating bovine endometritis, preparation method and application thereof | |
| CN104784311B (en) | Composition of medicine for preventing and treating animal aphtha hoof Huang and preparation method thereof | |
| Syed et al. | A successful treatment of bovine ulcerative mammilitis | |
| CN105193934B (en) | Compound essential oil for treating livestock endometritis and preparation method thereof | |
| CN101569697B (en) | Chinese traditional medicine for treating postpartum retained afterbirth of female animals | |
| CN105998220A (en) | Traditional Chinese veterinary material medicine for treating endometritis of cows as well as preparation method and use of traditional Chinese veterinary material medicine | |
| CN101327233B (en) | Compound external-use formulation for treating gonorrhoea and nongonococcal urethritis | |
| CN104784332B (en) | A kind of preparation method of the medicament treating Chronic Urinary Tract Infection | |
| CN112426436A (en) | Endometrium lotion and its application in treating endometritis | |
| CN103768104A (en) | Medicine for treating animal endometritis and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| EXSB | Decision made by sipo to initiate substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20170829 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |